Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitizone added onto their blinded study medication
Age
18–77
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes mellitus requiring treatment with at least 1500 mg but not greater than 2550 mg of a maximum tolerated dose of Metformin therapy for at least 8 weeks prior to screening.
HbA1c \>= 7.0% and \<= 10.0 %
Body mass index \<= 40 kg/m2
Fasting C-peptide \>= 1 ng/dL
You may not be if
Symptomatic poorly controlled diabetes
Recent cardiac or cerebrovascular event
Serum creatinine \>= 1.5 mg/dL for males and \>= 1.4 mg/dL for females